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Charmainne Cruje†,‡, Joy Dunmore-Buyze†,‡, Jarret P. MacDonald§, David W. Holdsworth†,‡, 
Maria Drangova†,‡, Elizabeth R. Gillies*,§,|| 
†Department of Medical Biophysics, ‡Robarts Research Institute, §Department of Chemistry, and 
||Department of Chemical and Biochemical Engineering, The University of Western Ontario, 
1151 Richmond Street, London, Ontario N6A 5B7, Canada 
ABSTRACT 
Despite recent technological advancements in microcomputed tomography (micro-CT) and 
contrast agent development, pre-clinical contrast agents are still predominantly iodine-based. 
Higher contrast can be achieved when using elements with higher atomic numbers, such as 
lanthanides; lanthanides also have x-ray attenuation properties that are ideal for spectral CT.  
However, the formulation of lanthanide-based contrast agents at the high concentrations required 
for vascular imaging presents a significant challenge. In this work, we developed an erbium-based 
contrast agent that meets micro-CT imaging requirements, which include colloidal stability upon 
redispersion at high concentrations, evasion of rapid renal clearance, and circulation times of tens 
of minutes in small animals. Through systematic studies with poly(ethylene glycol) (PEG)-
poly(propylene glycol), PEG-polycaprolactone, and PEG-poly(L-lactide) (PLA) block 
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copolymers, the amphiphilic block copolymer PEG114-PLA53 was identified to be ideal for 
encapsulating oleate-coated lanthanide-based nanoparticles for in vivo intravenous administration. 
We were able to synthesize a contrast agent containing 100 mg/mL of erbium that could be 
redispersed into colloidally stable nanoparticles in saline after lyophilization. Contrast 
enhancement of over 250 HU was achieved in the blood pool for up to an hour, thereby meeting 
the requirements of live animal micro-CT. 
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INTRODUCTION 
With the ultimate goal of developing methods to treat human disease, small animal models are 
used extensively in cardiovascular, orthopedic, and cancer research.1-3  The advantages of using 
small animals include short gestation times, low maintenance costs and ease of genetic 
manipulation.4 In order to study disease at scales suitable for small animals, high-resolution 
imaging techniques (i.e., micro-imaging) have been developed; these include micro magnetic 
resonance imaging,5, 6 micro positron emission tomography,7 micro-ultrasound,8, 9 and micro 
computed tomography (micro-CT).10 Among these, micro-CT has been the most utilized, based on 
scientific publications in the last five years. 
Micro-CT’s ubiquity is attributable to the fact that the modality is quantitative, three-
dimensional, non-destructive, fast and cost-effective. Contrast in micro-CT is derived from the 
differential attenuation of x-rays by various tissues. Unfortunately, soft tissues, which have similar 
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densities, have little differential CT contrast and exogenous agents are required to provide contrast.  
For example, to image the vasculature, x-ray attenuating contrast agents are injected intravenously 
to “opacify” the vessels during the acquisition of the micro-CT scan. With these contrast agents, 
vascular imaging by micro-CT can potentially be utilized to reliably track the development of 
blood vessels during the process of angiogenesis and in studying the effect of novel therapies for 
re-vascularization.11 For human imaging, CT contrast agents are typically small iodinated 
molecules, which are cleared within a few minutes through the renal system.  However, micro-CT 
scan times can be as long as tens of minutes and successful imaging of the vasculature requires the 
use of contrast agents that clear from the blood over extended time periods. These agents are 
referred to as “blood pool” contrast agents. 
Several CT blood pool contrast agents are available commercially for in vivo small animal 
research.12, 13 These have been made possible by advances in nanotechnology and consist of 
particles large enough to evade immediate renal clearance (i.e. > 10 nm).14 Initially, commercially 
available nanoparticle-based blood-pool contrast agents were iodine-based to take advantage of 
the strong attenuation of iodine at low energies (k-edge = 33.2 kEv) and included Fenestra VC 
(containing 50 mg/mL of iodine) and eXia 160 XL (containing 160 mg/mL of iodine).13, 15 More 
recently gold-based agents have been developed (e.g. AuroVist 15 nm, containing 200 mg/mL of 
gold), which take advantage of the high density of gold.16 These agents have been developed with 
the intent to deliver a high loading of metal (x-ray attenuator) in a small volume of contrast agent 
and thereby to provide higher contrast between the vessels and surrounding tissue. 
Another class of metals appropriate for CT contrast agents is the lanthanides.  These elements 
are of particular interest because they have k-edges near the average energies used in micro-CT 
(between 80 kVp and 120 kVp). This property makes the lanthanides ideally suited to use with 
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specialized micro-CT techniques that take advantage of the spectral properties of materials, such 
as dual-energy imaging and spectral CT. Of the lanthanides, gadolinium has been used most 
extensively as a contrast agent for magnetic resonance imaging (MRI). Polymer particles decorated 
with gadolinium, such as the chelated derivative of diethylenetriaminepentaacetic acid and Gd(III) 
on a cross linked polymer nanogel, have been synthesized and used for vessel imaging of mice, 
but have Gd loading that is too low for CT imaging (typically < 0.5 mg/mL).17-19  
Lanthanide-based nanoparticles have also been explored for imaging, largely due to their 
abilities to alter proton relaxation times in MRI in the case of gadolinium20, 21 or their photon 
upconversion capabilities in the case of NaLnF4 (where Ln is a lanthanide and the system is co-
doped).22-24 However, such particles are usually synthesized with hydrophobic ligands,25 making it 
challenging to disperse them with high stability in blood. Chatterjee et al. achieved this by coating 
lanthanide-based nanoparticles with polyethyleneimine, reaching concentrations of 4.4 mg/mL 
(used subcutaneously for upconversion luminescence imaging).22 Budijono et al. explored the 
encapsulation of lanthanide-based nanoparticles in block copolymer assemblies, and demonstrated 
the stability of these assemblies in serum media at low concentrations (< 1 mg/mL).24 Similary, 
Zhu et al. used pH-responsive block copolymers to encapsulate gadolinium-based nanoparticles, 
and demonstrated that they could stabilize the nanoparticles in aqueous solution at low 
concentrations (< 0.1 mg/mL).21  However, to date only Liu et al., have synthesized a lanthanide 
contrast agent with a concentration high enough for micro-CT imaging.26 They encapsulated 70 
mg/mL of ytterbium in 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-terminated 
poly(ethylene glycol) (PEG) and demonstrated circulation in the blood pool for approximately 20 
minutes.  However, even higher lanthanide concentrations and blood circulation times are required 
for high resolution imaging of the vasculature. 
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In this study, we present a simple and systematic method to prepare a lanthanide-based contrast 
agent for micro-CT applications, which require high contrast-element loading (> 100 mg/mL 
preferred) and long circulation times (ideally > 30 minutes). The high lanthanide concentration 
poses a significant challenge, particularly when paired with the need to add polymers, which are 
required to achieve long circulation times. Erbium, which we have demonstrated to be an excellent 
contrast agent for ex vivo imaging, was selected as the lanthanide.27 Oleate-coated NaErF4 
nanoparticles (ErNP) were synthesized and encapsulated into core-shell nanoassemblies via 
nanoprecipitation using a series of amphiphilic block copolymers (Figure 1). A sequence of 
optimization steps was then performed to identify an ideal polymer, which encapsulates a high 
lanthanide content while remaining colloidally stable after redispersion in saline and a mouse-
blood mimic. Once the ideal polymer was identified, the lanthanide-based contrast agent was 
evaluated in vivo over a period of one hour. To our knowledge, this is the first demonstration of 
the successful synthesis of an in vivo lanthanide-based blood pool agent that can be dispsersed into 
colloidally stable assemblies containing 100 mg/mL of erbium. 
 
 
Figure 1. Schematic representation of self-assembled erbium-based nanoparticles as a pre-clinical 
blood pool contrast agent. 
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EXPERIMENTAL SECTION 
Materials and General Methods 
Reagents were purchased from commercial suppliers as described in the Supporting Information 
(SI) and were used without further purification unless otherwise noted. Methods used in the 
synthesis and characterization of the materials are also presented in the SI document. 
 
Nanoprecipitation for self-assembly of polymeric nanoparticles containing erbium 
nanoparticles  
Erbium nanoparticles (ErNP) were synthesized by a previously reported method.28, 29 The ErNP 
were self-assembled with purchased poly(ethylene glycol) (PEG)-poly(propylene glycol) (PPG) 
triblock copolymers (PEG76-PPG22-PEG76 and PEG137-PPG34-PEG137 where the subscripts indicate 
the degree of polymerization of the blocks), or synthesized diblock copolymers of PEG-poly(e-
caprolactone)(PCL) (PEG45-PCL20, PEG45-PCL51, PEG114-PCL51, PEG114-PCL97) or PEG-poly(l-
lactide) (PEG45-PLA25, PEG45-PLA52, PEG114-PLA53, PEG114-PLA122).30, 31 ErNP (2 mg) were 
dissolved in 0.1 mL of tetrahydrofuran (THF).  Separately, 8 mg of copolymer was dissolved in 
0.1 mL of THF. These solutions were then combined and added dropwise to 1.8 mL of deionized 
water under magnetic stirring. After 1 hour, stirring was stopped and the solution was left uncapped 
for 12 hours to allow for organic solvent evaporation. The solutions were then dialyzed against 
100 mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to 
remove large aggregates and the samples were characterized by dynamic light scattering (DLS), 
transmission electron microscopy (TEM) and inductively coupled plasma mass spectrometry (ICP-
MS). 
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Colloidal stability of the polymeric nanoparticles 
The sterile polymeric nanoparticles containing ErNP were lyophilized prior to redispersion in 
saline. Saline is used as the solvent of the NPs prior to intravenous injection in vivo because it is 
isotonic with blood. Therefore the particles must remain colloidally stable in that environment. 
DLS size measurements were performed on the redispersed ErNP and the average sizes of the 
samples were observed for up to one hour. 
 
Varying the polymer content of the nanoparticles 
The polymeric nanoparticles containing ErNP that remained colloidally stable after freeze-
drying and redispersion in saline, and that encapsulated relatively higher erbium amounts were 
selected (PEG114-PLA53). Solutions with varying mass ratios were prepared. Synthesized ErNP 
(80 mg dissolved in 4 mL of THF) were added to 320, 160, 80 or 40 mg of PEG114-PLA53 in 4 mL 
of THF. These solutions were combined and added dropwise to 100 mL of deionized water under 
magnetic stirring. After 1 hour, stirring was stopped and the suspension was left uncapped for 12 
hours to allow for organic solvent evaporation. The suspensions were then dialyzed against 500 
mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to 
remove large aggregates and the samples were characterized by DLS, TEM and ICP-MS. The 
samples were lyophilized, sterilized and re-dispersed in 400 µL of saline. 10 µL of the samples 
were added to 990 µL of saline or mouse serum mimic for an hour-long time-course DLS study. 
The mouse serum mimic was pH 7.4 phosphate buffered saline containing 0.5 µg/mL mouse 
immunoglobulins, 1 wt%  bovine serum albumin and 0.1 wt% sodium azide. Colloidal stability in 
a mouse serum mimic in vitro will serve as an indicator of its stability in vivo. An increase in the 
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average size signifies aggregation, which would lead to immune system detection followed by 
clearance from the blood pool in vivo. 
 
General micro-CT imaging and analysis methods 
Micro-CT images were acquired using the GE Locus Ultra (London, ON) with a protocol 
previously used to evaluate contrast agent distribution in vivo.15, 32 Briefly, 1000 views (16 ms per 
view) were acquired at 80 kVp, 55 mA over 360° and reconstructed using a cone-beam 
reconstruction algorithm. The resulting images have a voxel size of 150 × 150 × 150 µm. Images 
were analyzed using MicroView (Parallax Innovations, London, ON) and CT contrast was 
reported in Hounsfield Units (HU – a standard linear scale of x-ray attenuation coefficient, where 
air = -1000 HU and water = 0 HU). All HU values were measured over a volume of 450 × 450 × 
150 µm. 
 
Micro-CT imaging of erbium-containing polymeric nanoparticles 
The relationship between CT contrast and erbium concentration was first determined by micro-
CT. Erbium chloride was diluted in saline at erbium concentrations of 5, 10, 20 and 100 mg/mL, 
which acted as calibration standards. The linear regression between CT contrast (in HU) and 
erbium concentration was then used to measure the erbium concentrations resulting when 40 mg 
of each of the lyophilized 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations were separately 
dispersed in 0.2 mL of saline.  
 
Toxicity of the contrast agent 
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The 1:1 and 0.5:1 PEG114-PLA53:ErNP mass ratio formulations were tested. Details of these 
experiments are described in the SI document. Briefly, an in vitro cell viability assay was done 
using C2C12 mouse myoblast cells from Millipore Sigma (Oakville, ON). The cells were 
incubated with the contrast agent for 24 hours, after which cell viability was measured using a 3-
(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  
Following in vitro tests, the in vivo toxicity of the contrast agent was evaluated using the dorsal 
interscapular subcutaneous tissue of C57BL/6 male mice (25-30 g). All animal studies were 
carried out in accordance with the regulations set out by the University of Western Ontario’s 
Council on Animal Care, in agreement with the ARRIVE guidelines, and were carried out in 
accordance with the U.K. Animals Act, 1986 and associated guidelines.  
 
Intravenous administration of the contrast agent and characterization of distribution in vivo 
Five C57BL/6 male mice (25-30 g) were anesthetized initially with 4% isoflurane, and then 
1.5% for maintenance, in O2 via a nose cone placed on the snouts of the animals. The tail veins 
were catheterized using PE-20 polyethylene tubing.  For each mouse, images were first acquired 
prior to contrast administration. The contrast agent (0.2 mL) was injected over a period of 
3 minutes and three scans were acquired, starting 2 minutes following the end of injection and 
ending 60 minutes post injection. The 1:1 PEG114-PLA53:ErNP (mass ratio) was tested in 3 mice 
and the 0.5:1 mass ratio formulation  was evaluated in 2 mice. 
 
RESULTS AND DISCUSSION 
Synthesis and characterization of oleate-coated ErNP 
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NaErF4 nanoparticles were synthesized based on a previously reported method.28, 29 DLS 
measurements of ErNP in THF reported a Z-average diameter of 50 ± 1 nm and a polydispersity 
index (PDI) of 0.18 ± 0.02 (Figure 2a and Figure S2). These results were supported by TEM 
imaging (Figure 2b). 
 
 
Figure 2. a) Volume diameter distribution of ErNP in THF measured by DLS. b) A TEM image of 
the oleate-coated ErNP. 
 
Synthesis and characterization of diblock copolymers 
The ErNP are oleate-coated, which makes them incompatible with the aqueous blood pool.33 It 
was envisioned that by nanoprecipitation of the ErNP with amphiphilic block copolymers, 
assemblies containing hydrophobic ErNP in the hydrophobic polymer cores and hydrophilic 
stabilizing polymer coronas would be formed (Figure 1). Polymers are relatively easy to prepare, 
are colloidally stable even at low concentration, and can be synthesized at different lengths using 
various monomers, making them tunable and versatile materials.34 We used PEG as the hydrophilic 
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block for its well-known stealth properties against the immune system.35, 36 In lieu of displacing 
the oleate on the ErNP surface with polymers,29, 37 we chose to synthesize polymeric micelles by 
nanoprecipitation, which is a fast, reproducible, and cost-effective means of suspending 
hydrophobic cargo in polar solvents.38 Displacing the oleate on the ErNP surface would favor the 
suspension of individual nanoparticles in solution, which is not a requirement in micro-CT. 
To identify a carrier that would encapsulate high erbium content while surviving lyophilization 
and redispersion in saline, a series of amphiphilic block copolymers was studied (Figure 3, Table 
1). Two PEG-PPG-PEG triblock copolymers (commonly referred to as poloxamers), which are 
commercially available, cost-effective and are FDA-approved for intravenous administration in 
humans, were used to form the polymeric assemblies.39 In addition, several block lengths of PEG-
PCL and PEG-PLA were synthesized and studied. These diblock copolymers were selected 
because they are used clinically as therapeutic drug carriers and are also currently in further clinical 
trials.40 The characteristics of the polymeric micelles may change upon varying the copolymer’s 
properties (i.e. hydrophobicity of the non-polar block, total block length, and PEG ratio).41 
 
 
Figure 3. Chemical structures of the amphiphilic block copolymers that were used to form the 
polymeric assemblies. 
 
 
12 
Table 1. SEC and 1H NMR characterization results of diblock copolymers. aDetermined by 1H 
NMR spectroscopy; bDetermined by SEC. 
 
PEG-PCL and PEG-PLA were synthesized using PEG monomethyl ether (2000 or 5000 g/mol) 
as the initiator and the block ratios were tuned by varying the equivalents of e-caprolactone or L-
lactide to achieve PEG mass fractions (f) of approximately 0.5 and 0.3. Methanesulfonic acid was 
used as the polymerization catalyst for the synthesis of PEG-PCL, while 1,5,7-
triazabicyclo[4.4.0]dec-5-ene was used as the catalyst for PEG-PLA synthesis.30, 31 A 1:1 ratio of 
catalyst:initiator was used in each case. Characterization of the diblock copolymers was performed 
using 1H nuclear magnetic resonance (NMR) spectroscopy (Figures S3-S10) and size exclusion 
chromatography (SEC) relative to polystyrene standards (Figures S11-S14) and the results are 
summarized in Table 1. Typical signals of PEG, PCL and PLA components were utilized to 
calculate the molar ratios of polymerized monomers to PEG and thus the number average 
Copolymer PEG molar mass (g/mol) 
Monomer 
feed (equiv.) 
PCL or PLA 
molar massa Mn
a Mnb Đb f valuea 
PEG76-PPG22-PEG76 6700 - - 8400 - - 0.80 
PEG137-PPG34-PEG137 12000 - - 14600 - - 0.82 
PEG45-PCL20 2000 18 2300 4300 5600 1.1 0.47 
PEG45-PCL51 2000 35 5800 7800 6300 1.4 0.26 
PEG114-PCL51 5000 44 5900 10900 9500 1.1 0.46 
PEG114-PCL97 5000 88 11100 16100 10300 1.3 0.31 
PEG45-PLA25 2000 22 2300 4300 5200 1.2 0.47 
PEG45-PLA52 2000 44 4700 6700 9600 1.1 0.30 
PEG114-PLA53 5000 56 4800 9800 10500 1.3 0.51 
PEG114-PLA122 5000 111 11000 16000 13500 1.4 0.31 
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molecular weight (Mn). The Mn and molar mass dispersities (Đ) were also measured by SEC. The 
f values were calculated from the NMR data, as this should provide the most accurate assessment 
of the block ratios. The values indicated for the poloxamers were taken from their respective 
specification sheets. Overall, the measured Mn values, particularly from NMR spectroscopy, and f 
values were in good agreement with the target structures.  
 
Polymer self-assembly and ErNP encapsulation 
First, the self-assembly of the block copolymers without ErNPs was investigated. The 
copolymers were dissolved in THF then this solution was added to water with stirring. After 
removal of THF by dialysis, the resulting nanoassemblies were characterized by DLS and TEM. 
The Z-average diameters measured by DLS ranged from 11 to 55 nm (Table 2, Figure S15), 
consistent with self-assembly into micelles and TEM images confirmed that solid spherical 
particles were formed (Figure S16). The PDIs ranged from 0.1 to 0.6, suggesting that some 
copolymers assembled into reasonably monodisperse nanoparticles (PDI < 0.3), whereas others 
exhibited a large distribution of sizes (PDI > 0.3). In general, the TEM results were in good 
agreement with the volume distributions obtained from DLS, except for both poloxamers (PEG76-
PPG22-PEG76 and PEG137-PPG34-PEG137). For these poloxamers, the volume distribution in DLS 
suggested the presence of small scatterers that could be unassembled copolymers in solution, 
whereas the corresponding TEM images showed larger nanoparticles that could result from 
aggregation during the drying process.  
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Table 2. Z-average diameters and PDIs obtained using DLS for the self-assembly of block 
copolymers without ErNP. Each assembly was prepared and measured in triplicate and the error 
measurements correspond to the standard deviations on these batches. 
Polymer Z-average diameter (nm) PDI 
PEG76-PPG22-PEG76 11 ± 2 0.6 ± 0.3 
PEG137-PPG34-PEG137 17 ± 3 1.0 ± 0.4 
PEG45-PCL20 20 ± 1 0.2 ± 0.1 
PEG45-PCL51 17 ± 2 0.1 ± 0.1 
PEG114-PCL51 18 ± 4 0.1 ± 0.1 
PEG114-PCL97 31 ± 4 0.2 ± 0.1 
PEG45-PLA25 26 ± 11 0.5 ± 0.2 
PEG45-PLA52 29 ± 8 0.4 ± 0.1 
PEG114-PLA122 31 ± 10 0.4 ± 0.2 
PEG114-PLA53 55 ± 8 0.2 ± 0.1 
 
 
Having confirmed the self-assembly behavior of the amphiphilic block copolymers alone, ErNPs 
were then added. Both the copolymer and ErNP were dissolved in THF and then nanoprecipitated 
into water to form suspensions of erbium-containing assemblies. The mass ratio of polymer:ErNP 
was 4:1. THF was removed by dialysis, then the suspensions were passed through a 0.45 µm filter. 
This filtration served to remove any ErNP that had not been encapsulated and consequently 
aggregated, as well as polymer-ErNP assemblies that were too large and would be preferentially 
cleared from the blood by the mononuclear phagocytic system (MPS).42, 43 The resulting assemblies 
were characterized by DLS and TEM (Figure 4, Table 3). The TEM images showed individual 
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ErNP or groups of ErNP across the grid, unlike the oleate-coated ones in Figure 2b, which 
displayed no specific organization or aggregation. This suggests the encapsulation of the ErNP 
within the amphiphilic block copolymers. It should be noted that the polymers were indiscernible 
in the TEM images because of the high contrast from the ErNP. The Z-average diameters that were 
measured by DLS ranged from 53 to 183 nm. This also supported the encapsulation of ErNP within 
the amphiphilic block copolymers, as these diameters were larger than those of the polymer-only 
micelles.  
When PEG114-PLA122 or any of the PEG-PCL diblock copolymers were used to form the 
assemblies, moderate PDIs (between 0.2 and 0.3) were observed. On the other hand, when using 
either poloxamers or the other PEG-PLA diblock copolymers good PDIs (< 0.2) were obtained. 
Because the contrast agent was simply required to remain in circulation (i.e. no tissue-targeting 
was required), obtaining low PDIs was not of utmost importance; meeting the size requirements 
that would allow evasion of immediate renal clearance and preferential uptake by the MPS was 
sufficient.  
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Figure 4. DLS volume (%) diameter distributions and the corresponding TEM images of polymer-
encapsulated ErNP using a) PEG76-PPG22-PEG76, b) PEG137-PPG34-PEG137, c) PEG45-PCL20, d) 
PEG45-PCL51, e) PEG114-PCL51, f) PEG114-PCL97, g) PEG45-PLA25, h) PEG45-PLA52, i) PEG114-
PLA53, and j) PEG114-PLA122. 
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Table 3. Characterization data for the polymer-encapsulated ErNP obtained from DLS and ICP-
MS both as initially prepared and after lyophilization followed by resuspension in saline. The 
polymer:ErNP mass ratios were 4:1 unless otherwise indicated. Each assembly was prepared and 
measured in triplicate and the error measurements correspond to the standard deviations on these 
batches. aDetermined by DLS; bDetermined by ICP-MS where 780 µg/L would correspond to 
encapsulation of 100% of the Er added during self-assembly. 
Polymer 
In water following initial 
preparationa 
Post-lyophilization and 
resuspension in salinea Erbium 
content (µg/L)b Z-average 
(nm) 
PDI Z-average 
(nm) 
PDI 
PEG76-PPG22-PEG76 174 ± 4 0.1 ± 0.1 294 ± 34 0.2 ± 0.1 62 ± 6 
PEG137-PPG34-PEG137 176 ± 6 0.1 ± 0.1 212 ± 2 0.2 ± 0.1 232 ± 1 
PEG45-PCL20 98 ± 10 0.3 ± 0.1 2145 ± 179 0.2 ± 0.1 377 ± 25 
PEG45-PCL51 82 ± 2 0.3 ± 0.1 3204 ± 416 0.2 ± 0.1 506 ± 3 
PEG114-PCL51 53 ± 5 0.3 ± 0.1 1057 ± 32 0.6 ± 0.1 596 ± 21 
PEG114-PCL97 84 ± 1 0.2 ± 0.1 2861 ± 9 0.4 ± 0.5 732 ± 22 
PEG45-PLA25 165 ± 2 0.1 ± 0.1 192 ± 4 0.5 ± 0.1 407 ± 2 
PEG45-PLA52 151 ± 2 0.2 ± 0.1 1597 ± 83 0.4 ± 0.1 149 ± 1 
PEG114-PLA122 130 ± 2 0.2 ± 0.1 301 ± 13 0.4 ± 0.1 339 ± 4 
PEG114-PLA53  154 ± 2 0.1 ± 0.1 134 ± 1 0.2 ± 0.1 599 ± 3 
PEG114-PLA53 (2:1) 180 ± 3 0.2 ± 0.1 180 ± 6 0.1 ± 0.1 583 ± 28 
PEG114-PLA53 (1:1) 179 ± 4 0.2 ± 0.1 171 ± 3 0.2 ± 0.1 607 ± 16 
PEG114-PLA53 (0.5:1) 183 ± 3 0.1 ± 0.1 185 ± 5 0.2 ± 0.1 533 ± 32 
 
 
18 
Redispersion and characterization of the lyophilized polymer-encapsulated ErNP  
Because the polymer-encapsulated ErNP were prepared by nanoprecipitation at low 
concentrations in water, the sample had to be lyophilized then redispersed at higher concentrations. 
The ability to lyophilize and resuspend the assemblies is also advantageous for their long-term 
storage. Dried samples were redispersed in 0.9% saline, which is isotonic with blood, and the Z-
average diameters of the assemblies were measured by DLS (Table 3). No filtration was performed 
after redispersion. In addition, because colloidal stability of the contrast agent in its administration 
medium is required, the Z-average diameters of the redispersed ErNP-loaded assemblies were also 
observed by DLS over 60 minutes.  
Relative to the pre-lyophilized diameters, minimal changes occurred for the PEG137-PPG34-
PEG137, PEG45-PLA25, and PEG114-PLA53 assemblies, while the remainder redispersed in saline at 
much larger hydrodynamic diameters, suggesting that they were aggregated. For example, the 
PEG76-PPG22-PEG76 assemblies, which initially had a Z-average hydrodynamic diameter of 174 ± 
4 nm had a diameter of 294 ± 34 nm after redispersion in saline, while the PEG137-PPG34-PEG137 
assemblies, which were initially 176 ± 6 nm, were redispersed in saline at 212 ± 2 nm (Figure 
S17). Given the very similar f values for these polymers, the larger PEG block is likely capable or 
better stabilizing the particles. All PEG-PCL assemblies redispersed in saline as micrometer-sized 
particles, which was undesirable, as these particles would be rapidly cleared by the MPS (Figure 
S18). The colloidal instabilities of PEG-PCL assemblies may result from PCL’s high 
hydrophobicity or crystallinity. The PEG45-PLA52 assemblies also redispersed as microparticles 
and PEG114-PLA122 assemblies redispersed at an increased Z-average diameter of 301 ± 13 nm 
compared to an initial diameter of 130 ± 2 nm (Figure S19). Both of these copolymers had low f 
values of ~0.3, which may contribute to their poor stability to redispersion. However, PEG45-PLA25 
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and PEG114-PLA53 assemblies retained Z-average diameters of 192 ± 4 and 134 ± 1 nm after 
redispersion in saline, similar to their initial diameters of 165 ± 2 and 154 ± 2 nm. Both remained 
colloidally stable for up to 60 minutes. This stability may result from their increased f values of 
~0.5. 
ICP-MS was used to quantify the concentration of erbium that was encapsulated by each system 
(Table 3). These measurements were performed on the initially prepared samples after their 
filtration. If all of the added erbium had remained dispersed in assemblies less than 0.45 µm in 
diameter, the expected erbium concentration of the suspensions would have been 780 µg/L. The 
highest erbium content was observed for PEG114-PCL97 at 732 ± 22 µg/L. The second highest 
concentration was obtained with PEG114-PLA53 at 599 ± 3 µg/L, then PEG114-PCL51 at 596 ± 21 
µg/L. However, out of the assemblies formed by these block copolymers, only PEG114-PLA53 
assemblies could be redispersed without a substantial increase in Z-average diameter in saline. The 
other block copolymers that allowed size consistency had lower erbium content, with PEG137-
PPG34-PEG137 at 232 ± 1 ug/L and PEG45-PLA25 at 407 ± 2 µg/L. Decreased erbium content 
resulted from the filtration of unencapsulated hydrophobic ErNP that aggregated in water or ErNP 
in assemblies larger than 0.45 µm in diameter. Based on this analysis, further studies were 
performed with PEG114-PLA53 as it was able to form stable assemblies with high erbium content.  
 
Characterization of the assemblies formed with PEG114-PLA53 
The polymer content of the contrast agent does not contribute to the attenuation of x-rays and 
hence will not contribute to higher contrast. It does however contribute to the total mass of the 
material in solution, and increases viscosity, thereby making administration of the suspension 
difficult. Thus, it would be desirable to decrease the polymer:ErNP ratio in the assemblies. 
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However, decreasing the polymer content of the assemblies has one drawback, which is the 
potential decrease of their stealthiness and immune system evasion.36 To investigate the possibility 
of lowering the polymer content of the contrast agent while retaining stability, assemblies were 
formed with lower PEG114-PLA53:ErNP mass ratios (from 4:1 to 2:1, 1:1 and 0.5:1).  Their colloidal 
stabilities at 37 °C in saline and in a mouse serum mimic were studied by DLS (Figure 5). The 
serum mimic contained bovine serum albumin and ions at concentrations that are similar to mouse 
blood. The proteins can potentially contribute to polymer shedding, and thereby to nanoparticle 
aggregation in vitro. In the blood pool of the animal in vivo, polymer shedding leads to the 
detection by the immune system and clearance of the nanoparticles from the blood via the liver.35, 
36 In the DLS analysis, the proteins generated insignificant scattering that did not interfere with the 
analysis of the assemblies (Figure S20-S21). The Z-average diameters for the initially prepared 
assemblies ranged from 121-185 nm and did not vary significantly over a period of 60 minutes in 
saline or in the mouse blood mimic, indicating that each formulation was sufficiently stable.  
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Figure 5. Time-course DLS results at 37 °C for PEG114-PLA53-encapsulated ErNP post-
lyophilization after redispersion in a) saline and b) mouse serum mimic.  
 
TEM imaging of the assemblies and analyses of their erbium content were also performed.  
Denser ErNP cores were observed when the polymer:ErNP ratio was reduced (Figure 6). Thus, 
decreasing the availability of polymers favored higher ErNP loading per assembly. ICP-MS results 
revealed similar erbium content in the suspensions for all of the mass ratios. Given this, and their 
colloidal stability in vitro, all the formulations should demonstrate similar contrast enhancement 
values over time once concentrated and administered to the blood pool. However, the concentrated 
solutions formed with polymer:ErNP mass ratios of 4:1 and 2:1 had high viscosities that made the 
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solutions too challenging to administer in vivo though the 30 G needles. Hence, for subsequent 
studies, the assemblies containing PEG114-PLA53:ErNP mass ratios of 1:1 and 0.5:1 were used. 
Using pyrene as a fluorescent probe,44 the critical aggregation concentrations (CACs) for these 1:1 
and 0.5:1  formulations were measured and compared to that of PEG114-PLA53 assemblies without 
ErNP. We found that the CAC of the block copolymer alone was 26 mg/L, whereas those of the 
1:1 and 0.5:1 PEG114-PLA53:ErNP formulations were 96 mg/L and 117 mg/L respectively (Figures 
S22-S24). Thus, it is evident that the loading of ErNP destabilizes the assemblies to some extent. 
Nevertheless, these CAC values are much lower than the concentrations at which they would be 
administered, even after dilution into the blood pool. 
 
 
 
Figure 6. TEM images of the PEG114-PLA53-encapsulated ErNP using polymer:ErNP mass ratios 
of a) 4:1, b) 2:1, c) 1:1, d) 0.5:1. 
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Erbium content in ErNP determined via Micro-CT 
While ICP-MS was used to detect erbium content before lyophilization, micro-CT was used to 
confirm the erbium content of the redispersed and high concentration versions of the contrast 
agents. A linear relationship between an element’s concentration and its attenuation of x-rays 
exists and does not depend on the specific chemical form of the element. This quantitative property 
of micro-CT contrast is one of its advantages as an imaging modality. Calibration standards 
containing erbium chloride dissolved in saline at concentrations of 0, 5, 10, 20 and 100 mg/mL of 
erbium were scanned. Using linear regression of the measured CT numbers of the standards 
(Figure S25), it was determined that 40 mg of the lyophilized 1:1 and 0.5:1 PEG114-PLA53:ErNP 
formulations dispersed in 0.2 mL of saline resulted in contrast element concentrations of 48 and 
74 mg/mL of erbium respectively. Therefore, 100 mg/mL is achieved when 42 mg of the 1:1 
formulation and 27 mg of the 0.5:1 formulation is suspended in 0.1 mL of saline. Micro-CT scans 
of the high concentration suspensions verified that 100 mg/mL of erbium was achieved when the 
calculated amount of the agent was used (Figure S26). While higher erbium loading can be 
achieved with more concentrated solutions, we restricted the experiments to 100 mg/mL in order 
to maintain low viscosities for intravenous injection in mice.  
 
Toxicity of the contrast agent  
The in vitro and in vivo toxicity of the contrast agent was evaluated prior to its intravenous 
administration. Based on MTT assays, greater than 80% viability relative to controls was observed 
for the 1:1 polymer to erbium mass ratio formulation up to concentrations of 0.5 mg/mL (Figure 
S27). The 0.5:1 polymer to erbium formulation was even less toxic, with greater than 80% viability 
up to 1 mg/mL, the highest concentration tested. We also performed subcutaneous injections to 
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study the materials in vivo. Subcutaneous tissue has slow absorption and clearance rates of 
exogenous materials, which provides an opportunity to study the reaction of tissues to the contrast 
agent over prolonged periods. Three-dimensional micro-CT images were obtained in mice before 
the subcutaneous injection of the 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations and two weeks 
after the administration of the agent. Each scan took 16 seconds to acquire. Representative micro-
CT images for each of the contrast agent formulation injections are shown in Figure S28. The 
images show that the contrast agent localized near the injection site for up to two weeks. Gross 
examination of the subcutaneous tissue confirmed the presence of some contrast agent near the 
injection site. No abnormalities were observed in either the subcutaneous tissue or the dermis 
(Figure S29).  
 
Distribution of the contrast agent in vivo 
Three-dimensional micro-CT images were obtained in mice before the intravenous 
administration of both contrast agent formulations and at three time points following the 
administration of the agent. Each scan took 16 seconds to acquire.  Representative micro-CT 
images for each of the contrast agents are shown in Figure 7. After contrast agent administration, 
all the major vessels – particularly the external jugular and axillary veins in Figure 7 – became 
clearly visible. For both formulations, there appeared to be no change in contrast in the chambers 
of the heart for up to 60 minutes. The contrast in the liver was seen as early as the 2-minute time 
point – demonstrated by the ability to distinguish liver from surrounding soft tissue.  
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Figure 7. Representative coronal micro-CT images showing the heart, liver, aorta, jugular veins 
and bladder of mice that received contrast agent formulated at a) 1:1 and b) 0.5:1 PEG114-
PLA53:ErNP mass ratios. All times are reported from the completion of the contrast agent injection. 
In the 2 minute image in a), the external jugular veins (double arrowheads) and the axillary veins 
(arrows) are clearly visible. 
 
Quantitative analysis indicated an increase in blood pool CT number of over 250 HU compared 
to pre-contrast values. The bladder was indistinguishable from pre-contrast values, indicating that 
the agent was not cleared through the renal system, as expected of materials that exceed the size 
of renal fenestrations.14 By the one-hour mark, the liver and the spleen had increased up to 180 ± 
15 HU and 278 ± 18 HU, respectively, for the 1:1 formulation, confirming the hypothesis that 
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large nanoparticles are cleared through the MPS.35, 36 In the myocardium, the CT number was just 
under 100 HU at all time points, which was expected of soft tissue in the absence of contrast 
material. As expected, the 0.5:1 polymer:ErNP assemblies demonstrated lower stealth activity, due 
to the lower amount of polymer used in the synthesis of the assembly, and were cleared from the 
blood more rapidly as indicated by the decreased intensity of the blood pool in the micro-CT 
images. Overall, this initial imaging study demonstrates that these new contrast agents can be 
dispersed and injected into mice at a concentration sufficient to achieve vascular contrast by micro-
CT in vivo. Furthermore, the particles exhibited sufficient stealth properties to circulate in the 
vasculature for at least 1 hour. This suggests the promise of these new lanthanide-based agents for 
applications such as dual-energy imaging and spectral CT. 
 
CONCLUSIONS 
In this study, by systematically comparing a series of amphiphilic block copolymers composed 
of different hydrophobic blocks and different PEG mass fractions, we identified PEG114-PLA53 as 
an amphiphilic copolymer that can encapsulate oleate-coated NaErF4 nanoparticles. The PEG114-
PLA53:ErNP assemblies redispersed into colloidally stable particles in saline after lyophilization 
and remained in the blood pool in vivo for at least an hour – a time period that well exceeds live 
animal micro-CT requirements. Importantly, we were able to formulate the assemblies at a high 
concentration of 100 mg/mL of erbium using PEG114-PLA53. At a delivered dose of 0.2 mL per 
mouse, this new contrast agent formulation resulted in the enhancement of blood pool in micro-
CT images (at 80 kVp) by approximately 250 HU (above a soft tissue baseline of 100 HU) for at 
least an hour following contrast agent administration. This system should be readily adaptable for 
a variety of lanthanides, as the metal can be easily substituted in the oleate-coated NaErF4 while 
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retaining very similar properties, suggesting its promise as a new class of contrast agents for micro-
CT as well as other imaging modalities such as MRI and optical imaging, in which lanthanides are 
utilized. Future studies will explore further the biodistribution and toxicity profiles of these agents. 
 
SUPPORTING INFORMATION 
Additional methods, DLS data, NMR spectra, SEC traces, and time-course size measurements. 
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